A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 320 participants.

Also called NCT07716618

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07716618
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07716618. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-17 (actual); primary completion 2026-05-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)
Intervention (Drug)
SAL0120 1mg
Intervention (Drug)
SAL0120 2mg
Intervention (Drug)
SAL0120 4mg
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)
Collaborator
Salubris (Suzhou) Pharmaceutical Co., Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct07716618
Content hash
51b24dbbaaf6ae6db4a8bf3745bb810dcd76492e9d8e5b68ba7c2b860cc4829c